Article

OccuLogix completes SOLX acquisition

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Based at the Boston University Photonics Center, SOLX developed the DeepLight Glaucoma Treatment System, including the DeepLight 790 Titanium Sapphire Laser and the DeepLight Gold Micro-Shunt, which can be used together or separately to reduce IOP. The system components have received international CE approval and are being studied in two randomized, multicenter trials in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.